AlphaCentric Advisors’s Innoviva INVA Stock Holding History

AlphaCentric Advisors’s Portfolio INVA Stock Details INVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-184,000	Closed	-$2.07M	–	249
2023 Q1	$2.07M	Buy	184,000 +109,000	+145%	+$1.32M	1.43%	16
2022 Q4	$994K	Buy	75,000 +7,000	+10%	+$92K	0.98%	36
2022 Q3	$789K	Buy	+68,000	New	+$932K	0.81%	40

Other funds holding INVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AlphaCentric Advisors's INVA Position: Q2 2023 in Review

AlphaCentric Advisors sold out of Innoviva (INVA) in Q2 2023, closing a stake of 184,000 shares — an estimated $2.07M sold.

AlphaCentric Advisors first reported a position in INVA in Q3 2022 and held it in 3 quarters. The position peaked at $2.07M in Q1 2023. 199 funds tracked by Wall St. Rank hold INVA as of Q2 2023.

AlphaCentric Advisors reported no remaining Innoviva position as of Q2 2023 after selling out during the quarter.
AlphaCentric Advisors sold 184,000 Innoviva shares in Q2 2023, an estimated $2.07M.
AlphaCentric Advisors first reported a position in Innoviva in Q3 2022 and held it in 3 quarters.
AlphaCentric Advisors's Innoviva position peaked at $2.07M in Q1 2023.
199 funds tracked by Wall St. Rank held Innoviva as of Q2 2023.

Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.